IMRX IMMUNEERING CORP

Immuneering Announces Participation in February Investor Conferences

Immuneering Announces Participation in February Investor Conferences

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company’s pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Immuneering will participate in the following investor conferences:

  • Guggenheim 6th Annual Biotechnology Conference (February 7 – 8, 2024)

    Format: Fireside chat and 1x1 investor meetings

    Fireside Chat: Wednesday, February 7 from 1:00 to 1:25 p.m. ET
  • Oppenheimer 34th Annual Healthcare Life Sciences Conference (February 13 – 14, 2024)

    Format: Virtual presentation and 1x1 investor meetings

    Virtual Presentation: Tuesday, February 13 from 3:20 to 3:50 p.m. ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at .

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit .

Media Contact:

Gina Nugent

Nugent Communications

617-460-3579

 

Investor Contacts:

Laurence Watts

Gilmartin Group

619-916-7620



or

Kiki Patel, PharmD

Gilmartin Group

332-895-3225



EN
01/02/2024

Underlying

IMRXIMMUNEERING CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMMUNEERING CORP

 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering Reports First Quarter 2025 Financial Results and Provides ...

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive data from the Company’s ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer, and as monotherapy in second-line pancreatic cancer - - Announced clinical trial supply agreement with Regeneron Pharmaceuticals to evalu...

May 5, 2025 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering to Present at the 24th Annual Needham Virtual Healthcare C...

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place from April 7-10, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, Brett Ha...

April 2, 2025 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Corporation Announces Grant of Inducement Award CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on March 20, 2025, that Igor Matushansky, M.D., Ph.D., was named Chief Medical Officer of the Company. In connection with the commencement of Dr. Matushanky’s employment, on March 21, 2025, Dr. Matushanky was granted an option to purchase 118,000 shares of the Company’s Class A comm...

March 21, 2025 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Result...

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a data updates and initiation of new IMM-1-104 combination arms expected in 2025; planning unde...

March 20, 2025 1 EN
 PRESS RELEASE
Free
IMRX IMMUNEERING COR...

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushansky, MD, PhD, has ...

March 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch